Real-life effects of medication and group therapy for ADHD and disruptive behaviors
Official title: Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders
Run by IRCCS Eugenio Medea · NCT07273695 · Data updated 2026-11-12
This project will test whether methylphenidate and/or group psychotherapy help children and adolescents (ages 8–15) with ADHD and emotional or behavioral dysregulation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 8 Years to 15 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | IRCCS Eugenio Medea Academic / other |
| Locations | 1 site (Bosisio Parini, Lecco) |
| Status | Recruiting |
| Started | September 19, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07273695 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adolescents aged 8–15 with a clinical diagnosis of ADHD, externalizing disorder, and/or emotional dysregulation and an IQ ≥ 75 are the intended participants.
✕Probably not a fit
Children with IQ below 75, active psychosis, significant neurological disease (including epilepsy), substance abuse, or certain genetic syndromes are unlikely to be appropriate or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter observational project follows children and adolescents (8–15) with ADHD, externalizing disorders, or emotional dysregulation who receive pharmacological (methylphenidate) and/or group psychotherapeutic treatments. Participants undergo multimodal assessments including clinical scales, behavioral tests, and neural measures before and after treatment, with both prospective and retrospective data collection. The design is non-randomized and non-blinded and compares real-world responses to medication versus group psychotherapy to measure symptom changes. Analyses will seek associations between individual characteristics and treatment responses to generate predictive profiles that could guide more personalized interventions.
Why it matters
Potential benefit: If successful, the project could help clinicians match children to medication or group therapy that is more likely to reduce ADHD and behavioral dysregulation symptoms.
How similar studies have gone: Randomized trials have shown methylphenidate reliably reduces core ADHD symptoms and some behavioral problems, group psychotherapies have shown mixed but promising effects, and using multimodal neural and behavioral measures to predict individual treatment response is a growing but still exploratory approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Children and adolescents aged 8-15 years; * Diagnosis of externalizing disorder, ADHD, and/or emotional dysregulation (assessed with questionnaires, interviews, and/or clinical observation); * Intelligence quotient ≥ 75. Exclusion Criteria * IQ \< 75; * Substance abuse and addictions; * Psychosis; * Acute disorders; * Organic brain disorders; * Presence of neurological diseases, epilepsy; * Genetic syndromes; * Co-diagnosis with other psychiatric or neurodevelopmental disorders (e.g., autism, anxiety, depression, etc.) and prior psychopharmacological therapy will not be considered exclusion criteria but will be recorded and declared.
Where it's running
-
IRCCS E Medea Scientific Institute - Asssociazione La Nostra Famiglia
Bosisio Parini, Lecco, Italy Recruiting
Study contacts
- Principal investigator: Maria Nobile, PhD, MD — IRCCS E Medea Scientific Institute
- Study coordinator: Maria Nobile, PhD, MD
- Email: maria.nobile@lanostrafamiglia.it
- Phone: +39031877563
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Healing Hearts: A Mindfulness App for Parents Navigating Divorce or Separation
A online program tests a self-guided mindfulness app for distressed parents going through divorce or separation, to see if it helps parent and child wellbeing.
-
Augmenting Parent Management Training with a Smartphone Tool
This study tests whether adding a smartphone app to parent management training helps reduce irritability and temper outbursts in kids aged 8–13 with disruptive behavior disorders.
-
Centanafadine in adults with ADHD and emotional dysregulation
This study tests centanafadine XR once daily to see if it helps adults with ADHD who also have emotional dysregulation.
-
NLP-based weekly writings to track mood and worry during residential rehab for SUD
This study tests whether weekly Spanish narratives and biweekly questionnaires can reveal patterns of mood and thoughts that relate to recovery in adults with substance use disorders in a Mexican rehab center.
-
Behavioral parent training with optional AI support for children with disruptive behaviors
This trial will test whether adding a 24/7 AI assistant to online group behavioral parent training helps parents manage children aged 5–12 with disruptive behaviors.
-
Parent–Adolescent Relationships, Heart Rate Variability, and Emotional Regulation in Teens with Depression
This study looks at whether teen sleep heart rate variability relates to emotional regulation and the quality of parent–teen relationships in adolescents with depression, using a Fitbit at night for a week.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.